Early access
Sign in
Taking people in FinlandPhase 2

Tests SUN-627 in adults with progressive multiple sclerosis

Tests SUN-627 for safety in adults with non-active progressive multiple sclerosis.

Key facts

Who runs it
Sundance Biosciences Inc.
Where
Turku, FinlandSee the site
Registry title
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
5 Oct 2026
Expected to end
30 Apr 2027
Type of study
Interventional
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-70 with primary progressive MS or non-active secondary progressive MS that has kept getting worse over time.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Primary progressive MS (PPMS) or non-active secondary progressive MS (SPMS). No MS relapses in the past 2 years. The MS has continued to get worse over time. The level of disability must fit the study requirements.
Earlier treatment
Certain medications or treatments before the study, or needed during the study, rule people out. The record does not list which ones.

Main reasons for not taking part

  • Use of certain medications or treatments before or during the study
  • Taking part in another research study right now
  • Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
  • Certain serious or unstable medical conditions that could make the study unsafe
  • Active infection, recent infection, or repeated infections in the past

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Aged 18-70, inclusive
  • Diagnosis of PPMS or non-active SPMS
  • No MS relapses in the past 2 years
  • Evidence that MS has continued to get worse over time
  • A level of disability that fits the study requirements
  • Additional inclusion criteria are outlined in the full study protocol

Who cannot take part

  • Use of certain medications or treatments before the study, or need for these treatments during the study
  • Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
  • Certain serious or unstable medical conditions that could make the study unsafe
  • Active infection, recent infection, or a history of repeated infections
  • Current participation in another research study
  • Additional exclusion criteria are outlined in the full study protocol

Where in Finland

  • Turku University HospitalTurku, FinlandTaking people

About the trial

What the trial wants to find out

To assess safety and tolerability of SUN-627

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Plain-language title
Tests SUN-627 in adults with progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2026